Comparison · NCT00770653-2723f27b
Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID: Intake of Study Medication Greater Than 80% and Less Than 120%.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID: Intake of Study Medication Greater Than 80% and Less Than 120%. Trial comparisons, record NCT00770653-2723f27b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00770653-2723f27b
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.932 | 0.879 | 0.962 | wilson | |
| Risk in group 2 | 0.965 | 0.92 | 0.985 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0333 | -0.09 | 0.0209 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.966 | 0.915 | 1.02 | log | |
| Odds ratio, group 1 over group 2 | 0.496 | 0.165 | 1.49 | log | |
| Number needed to treat, for one fewer participant with the outcome on Pioglitazone 15 mg and Metformin 850 mg BID than on Glimepiride 2 mg and Metformin 850 mg BID | 30 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Pioglitazone 15 mg and Metformin 850 mg BID | Pioglitazone 15 mg/metformin 850 mg combination tablets, orally, twice daily and glimepiride placebo-matching tablets, orally, once daily and metformin placebo-matching tablets, orally, twice daily for up to 24 weeks. | 136 | 146 | OG000 |
| Group 2 | Glimepiride 2 mg and Metformin 850 mg BID | Pioglitazone/metformin placebo-matching combination tablets, orally, twice daily and glimepiride 2 mg, tablets, orally, once daily and metformin 850 mg, tablets, orally, twice daily for up to 24 weeks. | 137 | 142 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Intake of Study Medication Greater Than 80% and Less Than 120%.
- Description
- The change between the Intake of study medication greater than 80% at week 24 or final visit and Baseline and the Intake of study medication greater than 80% at baseline.
- Time frame
- Baseline and Week 24.
- Population
Analyses was performed for the full analysis and per-protocol set. This condition was not fulfilled in some participants who were excluded. Last observation carried forward was used (LOCF) in case of premature termination.
Source ClinicalTrials.gov
Trial
- Title
- Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.
- NCT number
- NCT00770653
- Phases
- PHASE3
- Conditions
- Diabetes Mellitus, Dyslipidemias
- Interventions
- Pioglitazone and Metformin, Glimepiride and Metformin
- Lead sponsor
- Takeda
- Results first posted
- 2010-10-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00770653?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00770653-2723f27b